Skip to main content

Share story

Science

Siren Biotechnology receives $8M CIRM grant for AAV gene therapy brain cancer trial

Siren Biotechnology announced on X on June 26, 2026, that it has been awarded an $8 million non-dilutive CLIN2 grant from the California Institute for Regenerative Medicine. The grant will support the company's Phase 1/2 clinical trial of SRN-101 in adult patients with recurrent high-grade glioma. The post from the account @SirenBio stated the funding comes from CIRM and thanked the organization along with the support of Californians. The announcement included a link to a press release and used the hashtag #cancer. The post was made by Siren Biotechnology, Inc.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from SirenBio and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Products
Products

Quest Global acquires wearable testing provider Tests Assured

Quest Global has acquired Tests Assured, adding specialized testing for wearable devices, immersive technologies, and connected hardware and software to its engineering services business. The U.S. company tests smart glasses and augmented, virtual and extended reality products.

Capital Infrastructure
Capital Infrastructure

Mavria raises $130M for truck-shippable data centers

Mavria raised $130M across pre-seed and seed rounds at a $1B valuation, with Paradigm leading the financing, The Wall Street Journal reported. The company aims to build modular data centers that can be shipped by truck.